drugset / Trial / NCT03433183
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Phase 2
Completed
21 enrolled
Sarcoma Alliance for Research through Collaboration
AstraZeneca · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
To determine the clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic neurofibromatosis type 1 (NF1) associated or sporadic MPNST.
Timeline
- Start
- 2019-10-02
- Primary completion
- 2022-06-22
- Completion
- 2023-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selumetinib | Small molecule | 50 mg | Oral |
| Subject | Sirolimus | Small molecule | 4 mg | Oral |